Veracyte (VCYT)

The company is best known for diagnostic and prognostic products in oncology. Its Afirma test supports the evaluation of thyroid nodules, helping identify which patients may be able to avoid unnecessary surgery. Decipher Prostate provides genomic information used in assessing prostate cancer aggressiveness and guiding treatment decisions. Veracyte also offers tests for breast cancer through Prosigna and for bladder cancer through Decipher Bladder, extending its platform across several major cancer categories.

Veracyte’s approach reflects a broader shift in medicine toward precision diagnostics, where treatment pathways are increasingly informed by genomic signatures and disease biology rather than by anatomy or histology alone. By producing clinically actionable information, the company aims to support earlier, more accurate decisions and reduce overtreatment or undertreatment.

The business operates at the intersection of laboratory diagnostics, molecular biology, oncology, and healthcare reimbursement. Its commercial success depends on physician adoption, clinical evidence, payer coverage, guideline inclusion, and the ability to integrate tests into routine care pathways.

For investors, Veracyte offers exposure to the growth of genomic testing in cancer care. The company is distinctive because its products are not simply research tools; they are intended to answer practical clinical questions that affect whether patients undergo surgery, receive specific therapies, or follow more intensive monitoring strategies.